- Home
- DMO vs BDTX Comparison
DMO vs BDTX Comparison
Compare DMO & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DMO | BDTX |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 123.3M | 116.8M |
| IPO Year | 2009 | 2020 |
Fundamental Metrics
Financial Performance| Metric | DMO | BDTX |
|---|---|---|
| Price | $11.15 | $2.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $9.50 |
| AVG Volume (30 Days) | 44.3K | ★ 579.2K |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 130.71 |
| EPS | N/A | ★ 0.39 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $6.97 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.42 | $1.31 |
| 52 Week High | $12.11 | $4.94 |
Technical Indicators
Market Signals| Indicator | DMO | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 60.73 | 64.71 |
| Support Level | $11.07 | $2.45 |
| Resistance Level | $11.42 | $2.86 |
| Average True Range (ATR) | 0.18 | 0.15 |
| MACD | 0.06 | 0.06 |
| Stochastic Oscillator | 89.04 | 88.00 |
Price Performance
Historical ComparisonAbout DMO Western Asset Mortgage Opportunity Fund Inc.
Western Asset Mortgage Defined Opportunity Fund Inc is a non-diversified, limited-term, closed-end management investment company. The fund's primary investment objective is to provide current income. As a secondary investment objective, the Fund will seek capital appreciation. The Fund seeks to achieve its investment objectives by investing in a diverse portfolio of mortgage-backed securities, consisting of non-agency residential mortgage-backed securities and commercial mortgage-backed securities.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.